EcoDrugPlus

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSSAG00000078752
Gene Symbol: HTR1B
2 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSSAG00000072056
Gene Symbol: HTR1B
5 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSSSAG00000079194
Gene Symbol: HTR1E
5 Cross references
139 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSSSAG00000107368
Gene Symbol: HTR1E
5 Cross references
139 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSSSAG00000003618
Gene Symbol: HTR1E
2 Cross references
115 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSSSAG00000054049
Gene Symbol: HTR1F
5 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSSSAG00000088280
Gene Symbol: HTR2A
4 Cross references
211 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSSSAG00000091455
Gene Symbol: HTR2A
5 Cross references
212 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b-Like

Ensembl ID : ENSSSAG00000080601
Gene Symbol: LOC106613493
5 Cross references
195 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSSSAG00000094372
Gene Symbol: LOC106578039
4 Cross references
195 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSSSAG00000064523
Gene Symbol: HTR3A
5 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSSSAG00000016481
Gene Symbol: HTR3A
2 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).